MAINZ, Germany & BioNTech and Pfizer Inc. on April 9, 2020, disclosed additional details of their collaboration for advancing the candidates from mRNA vaccine program of BioNTech, previously announced on March 17, 2020.
This collaboration is aimed at rapidly advancing multiple COVID-19 vaccine candidates into human clinical testing based on the proprietary mRNA vaccine platforms of BioNTech to ensure rapid worldwide access to the vaccine, once approved. This partnership will leverage the expertise of Pfizer in vaccine R&D, regulatory capabilities, as well as the global manufacturing and distribution network.
BioNTech and Pfizer will jointly be conducting clinical trials for the coronavirus vaccine candidates in the US and Europe across multiple sites. BioNTech and Pfizer will initiate the first clinical trials by the end of April 2020.
During the clinical development stage, clinical supply of the vaccine will be provided by the BioNTech’s Europe’s GMP-certified mRNA manufacturing facilities. The companies involved in the collaboration will be working together for scaling-up manufacturing capacity at risk to provide the global supply in response to the outbreak. BioNTech and Pfizer will also work jointly for the commercialization of the vaccine across the globe (except China, as it is already covered by the collaboration of BioNTech with Fosun Pharma).
About Pfizer
Pfizer Inc. is a research-based global biopharmaceutical company whose global portfolio includes medicines and vaccines. The company operates through two business segments: Pfizer Innovative Health (IH) that focus on develop and commercialize medicines and vaccines, Pfizer Essential Health (EH) that includes legacy brands, branded generics, generic sterile injectable products, biosimilars, and infusion systems.
About BioNTech
BioNTech is a next generation immunotherapy company that is involved in the development of novel therapies for the treatment of cancer and other serious diseases. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, which include Eli Lilly and Company, Bayer Animal Health, Genmab, Sanofi, Genentech, a member of the Roche Group, Genevant, Fosun, and Pfizer.
